174 related articles for article (PubMed ID: 9784876)
1. Discovering transthyretin amyloid fibril inhibitors by limited screening.
Baures PW; Peterson SA; Kelly JW
Bioorg Med Chem; 1998 Aug; 6(8):1389-401. PubMed ID: 9784876
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022
[TBL] [Abstract][Full Text] [Related]
3. Rational design of potent human transthyretin amyloid disease inhibitors.
Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.
Oza VB; Petrassi HM; Purkey HE; Kelly JW
Bioorg Med Chem Lett; 1999 Jan; 9(1):1-6. PubMed ID: 9990446
[TBL] [Abstract][Full Text] [Related]
5. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid.
Baures PW; Oza VB; Peterson SA; Kelly JW
Bioorg Med Chem; 1999 Jul; 7(7):1339-47. PubMed ID: 10465408
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
8. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Arsequell G; Planas A
Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
10. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
[TBL] [Abstract][Full Text] [Related]
12. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
[TBL] [Abstract][Full Text] [Related]
13. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Tojo K; Sekijima Y; Kelly JW; Ikeda S
Neurosci Res; 2006 Dec; 56(4):441-9. PubMed ID: 17028027
[TBL] [Abstract][Full Text] [Related]
14. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
15. The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?
Zhong B; Huang X; Zheng Y; Guo X; Wu L
Future Med Chem; 2021 Dec; 13(23):2083-2105. PubMed ID: 34633220
[TBL] [Abstract][Full Text] [Related]
16. Potential treatment of transthyretin-type amyloidoses by sulfite.
Altland K; Winter P
Neurogenetics; 1999 Sep; 2(3):183-8. PubMed ID: 10541593
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
[TBL] [Abstract][Full Text] [Related]
19. TTR fibril formation inhibitors: is there a SAR?
Nencetti S; Orlandini E
Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
Ciccone L; Nencetti S; Rossello A; Stura EA; Orlandini E
J Enzyme Inhib Med Chem; 2016; 31(sup1):40-51. PubMed ID: 27067161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
